Advagene Biopharma Co., Ltd. (TPEX:6709)
Taiwan · Delayed Price · Currency is TWD 28.35
+2.00 (7.59%)
Jan 22, 2026, 1:52 PM CST
Advagene Biopharma Company Description
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan.
It engages in the development of nasal spray influenza vaccine; respiratory allergy treatment vaccine, including rhinitis and asthma; COVID-19 immunotherapy; and other vaccines.
The company was founded in 2006 and is based in Taipei, Taiwan.
Advagene Biopharma Co., Ltd.
| Country | Taiwan |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Yu-Shen Hsu |
Contact Details
Address: No.308, Neihu Road Taipei, 114 Taiwan | |
| Phone | 886 2 2797 0073 |
| Website | advagene.com.tw |
Stock Details
| Ticker Symbol | 6709 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006709009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yu-Shen Hsu | Acting President, GM and Director |
| Chen Bryon | Founder and Director |
| Kuangdun Su | Accounting Supervisor |
| Frank Hsiao | Executive Vice President |
| Pongo Peng | Executive Vice President |